Adults with type 2 diabetes and BMI ≤30 kg/m2 initiating GLP-1 RAs or dipeptidyl peptidase-4 inhibitors (DPP-4i) between 2016 and 2023 were identified. Here, GLP1R is linked to type 2 diabetes mellitus.